Breakthrough: NIH Funds Alzheimer’s Drug AD04 with $2.5M
ADvantage Therapeutics secured a $2.5 million Phase II SBIR grant from the National Institute on Aging to advance AD04,...
eClinical Tech News
Immuneering to Discuss Pancreatic Cancer Survival Data
Updated overall survival and safety data from a 34‑patient, first‑line pancreatic cancer cohort treated with atebimetinib plus modified gemcitabine/nab‑paclitaxel...
Groundbreaking Data: Revita Maintains Weight Loss Post-GLP-1
In a randomized, double-blind, sham-controlled midpoint cohort of REMAIN-1 (N=45), Revita produced an additional 2.5% total body weight loss...
Cidara Doses Patients in Phase 3 Flu Prevention Trial
Cidara has begun dosing in ANCHOR, a global Phase 3 trial of CD388, a single 450 mg subcutaneous dose...
First Fully Robotic GI Procedure by a Gastroenterologist
In the PARADIGM pivotal IDE trial, a gastroenterologist completed the first fully robotic endoscopic submucosal dissection using EndoQuest’s Endoluminal...
RenovoRx Panther Study Progresses with First Clinical Procedure
RenovoRx has initiated its PanTheR post-marketing registry with the first registry-eligible patient procedure completed at the University of Vermont...
New Data: CNM-Au8 Improves Brain Energy Metabolism in MS
Topline data: In the combined Phase 2 REPAIR program, 12 weeks of CNM-Au8 increased the brain NAD+/NADH ratio by...
Varmx Receives Key Phase 1 Waiver from Japan’s PMDA
Japan’s PMDA has waived the requirement for a domestic Phase 1 (ethnic bridging) study for VarmX’s VMX-C001, clearing the...
SAPU003 Trial: Full Everolimus Bioavailability for Cancer
Oral everolimus delivers roughly 10% bioavailability; Sapu003, an intravenous formulation, is designed to bypass absorption limits and deliver full...
New Drug Shows 86% Survival in Pancreatic Cancer Patients
Topline: In a single-arm Phase 2a cohort (N=34) of first-line pancreatic cancer, atebimetinib (IMM-1-104) plus modified gemcitabine/nab-paclitaxel delivered 86%...